Théa Pharma announced that Iyuzeh (latanoprost ophthalmic solution) 0.005% demonstrated similar IOP lowering efficacy with a favorable safety profile when compared to Xalatan (latanoprost ophthalmic solution) 0.005% (Mylan) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), in a phase 3 study. Jason Bacharach, MD, founder and director of research at North Bay Eye Associates in Petaluma, California, presented the study outcomes at the 2023 annual American Glaucoma Society (AGS) meeting. Iyuzeh was compared to Xalatan in 334 patients over 84 days.

“Iyuzeh demonstrated similar clinically meaningful reductions in IOP from baseline (≤18 mmHg) with fewer ocular adverse events (13.9% vs 22.5%),” Dr. Bacharach said in a news release. Less than 2% of patients in the Iyuzeh group experienced instillation site pain, pruritis, or conjunctival hyperemia. Iyuzeh is the first and only preservative-free latanoprost ophthalmic solution.

“We have solved the challenge of creating a room temperature–stable, efficacious, and preservative-free latanoprost eye drop. Iyuzeh brings the IOP-lowering efficacy of latanoprost and eliminates the exposure to preservatives for patients with glaucoma or OHT,” Susan Benton, president of Théa Pharma, said in a news release.

Iyuzeh is marketed outside of the United States in 46 countries under the brand name Monoprost, which was launched 10 years ago.